Thus, this study not only improves our understanding of molecular mechanisms underlying CTC formation in early BC patients but also provides insight into the therapeutic potential of targeting the FOXD1-dependent ERK1/2 signaling cascade though further understanding this complexity will require a broader view of underlying signal transduction in the future. This evidence concerns the gene MAPK3 and breast cancer.